Abstract

In this study, we investigated the role of CD38 in a pristane-induced murine model of lupus. CD38-deficient (Cd38−/−) but not ART2-deficient (Art2−/−) mice developed less severe lupus compared to wild type (WT) mice, and their protective phenotype consisted of (i) decreased IFN-I-stimulated gene expression, (ii) decreased numbers of peritoneal CCR2hiLy6Chi inflammatory monocytes, TNF-α-producing Ly6G+ neutrophils and Ly6Clo monocytes/macrophages, (iii) decreased production of anti-single-stranded DNA and anti-nRNP autoantibodies, and (iv) ameliorated glomerulonephritis. Cd38−/− pristane-elicited peritoneal exudate cells had defective CCL2 and TNF-α secretion following TLR7 stimulation. However, Tnf-α and Cxcl12 gene expression in Cd38−/− bone marrow (BM) cells was intact, suggesting a CD38-independent TLR7/TNF-α/CXCL12 axis in the BM. Chemotactic responses of Cd38−/− Ly6Chi monocytes and Ly6G+ neutrophils were not impaired. However, Cd38−/− Ly6Chi monocytes and Ly6Clo monocytes/macrophages had defective apoptosis-mediated cell death. Importantly, mice lacking the cation channel TRPM2 (Trpm2−/−) exhibited very similar protection, with decreased numbers of PECs, and apoptotic Ly6Chi monocytes and Ly6Clo monocytes/macrophages compared to WT mice. These findings reveal a new role for CD38 in promoting aberrant inflammation and lupus-like autoimmunity via an apoptosis-driven mechanism. Furthermore, given the implications of CD38 in the activation of TRPM2, our data suggest that CD38 modulation of pristane-induced apoptosis is TRPM2-dependent.

Details

Title
CD38 promotes pristane-induced chronic inflammation and increases susceptibility to experimental lupus by an apoptosis-driven and TRPM2-dependent mechanism
Author
García-Rodríguez, Sonia 1 ; Rosal-Vela, Antonio 1 ; Botta, Davide 2   VIAFID ORCID Logo  ; Cumba Garcia, Luz M 3 ; Zumaquero, Esther 2 ; Prados-Maniviesa, Verónica 1 ; Cerezo-Wallis, Daniela 4 ; Nicola Lo Buono 5   VIAFID ORCID Logo  ; Robles-Guirado, José-Ángel 1 ; Guerrero, Salvador 6 ; González-Paredes, Elena 1 ; Andrés-León, Eduardo 7   VIAFID ORCID Logo  ; Corbí, Ángel 8 ; Mack, Matthias 9 ; Koch-Nolte, Friedrich 10 ; Merino, Ramón 11 ; Zubiaur, Mercedes 1 ; Lund, Frances E 2 ; Sancho, Jaime 1   VIAFID ORCID Logo 

 Department of Cellular Biology and Immunology, IPBLN-CSIC, Granada, Spain 
 Department of Microbiology, UAB, Birmingham, Alabama, USA 
 Department of Cellular Biology and Immunology, IPBLN-CSIC, Granada, Spain; Immunology Graduate Program, Mayo Clinic, Rochester, MN, USA 
 Department of Cellular Biology and Immunology, IPBLN-CSIC, Granada, Spain; Melanoma Group, CNIO, Madrid, Spain 
 Department of Cellular Biology and Immunology, IPBLN-CSIC, Granada, Spain; Laboratory of Immune-mediated Diseases, San Raffaele Diabetes Research Institute (DRI), Milano, Italy 
 Flow Cytometry Unit, IPBLN-CSIC, Granada, Spain 
 Bioinformatics Unit, IPBLN-CSIC, Granada, Spain 
 Department of Molecular Microbiology and Infection Biology, CIB-CSIC, Madrid, Spain 
 Department of Internal Medicine II, Nephrology, Regensburg University Medical Center, Regensburg, Germany 
10  Institute of Immunology, University Medical Center Eppendorf-Hamburg, Hamburg, Germany 
11  Department of Molecular and Cellular Signalling, IBBTEC-CSIC-UC, Santander, Spain 
Pages
1-19
Publication year
2018
Publication date
Feb 2018
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2006814710
Copyright
© 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.